pharmaphorum

JANUARY 12, 2023

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.

Insulin 58

Insulin Trials Development Drugs 58

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. cases of hypoglycaemia per year with insulin icodec, versus 0.27 In absolute terms, there were 0.73 events for the once-daily drug.

Insulin 98

Insulin Trials Drugs Production 98

BioPharma Reporter

JANUARY 29, 2024

Synthetic biology company rBIO has completed all required analytical characterizations of its insulin biosimilar, R-biolin.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

Drug Discovery World

FEBRUARY 19, 2024

Preclinical data has demonstrated insulin independence following transplantation of hypoimmune (HIP) allogeneic primary islet cells without immunosuppression in a diabetic non-human primate (NHP). Following this, blood glucose levels in the diabetic NHP began to fluctuate and increase markedly, and insulin injections needed to be resumed.

Insulin 52

Insulin Immune Response Engineer Antibody 52

pharmaphorum

OCTOBER 4, 2022

Danish company Novo Nordisk have announced positive results from the ONWARDS 5 phase 3 trial, with once-weekly insulin icodec demonstrating superior reduction of HbA1 in people with type 2 diabetes, in combination with a dosing guide app.

Insulin 58

Insulin Trials Clinical Trials Clinical Trials 58

The Pharma Data

APRIL 28, 2022

Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from daily insulin. events per patient-year exposed to insulin degludec.

Insulin 52

Insulin Trials Clinical Trials Clinical Trials 52

Fierce Pharma

NOVEMBER 8, 2023

While Novo Nordisk struggles with manufacturing concerns and patient coverage on its long-acting insulin Levemir, Bayer missed a primary endpoint in a confirmatory trial for its P13K inhibitor Aliq | While Bayer's P13K Aliqopa couldn't prove its worth in a confirmatory trial, Novo's Levemir faced manufacturing issues and troubles with (..)

Insulin 52

Insulin Manufacturing Marketing Trials 52

pharmaphorum

DECEMBER 7, 2023

Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, potentially opening up a whole new avenue of therapy.

Insulin 115

Insulin Trials 115

pharmaphorum

SEPTEMBER 22, 2022

Insulin has been used to manage diabetes for a century, and while many advances have been made for people with both type 1 and type 2 diabetes – many more continue to be made. The post How a once-weekly insulin could disrupt diabetes management – the pharmaphorum podcast appeared first on.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

Scienmag

JANUARY 26, 2021

publishers New Rochelle, NY, January 26, 2021–Hybrid closed-loop insulin therapy improved glycemic control in adolescents and young adults with type 1 diabetes. These outcomes, derived from the International Diabetes Closed-Loop (iDCL) Trial, are reported in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT).

Insulin 55

Insulin Trials Gene Therapy Clinical Trials 55

BioTech 365

SEPTEMBER 20, 2021

Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes … Continue reading →

Insulin 40

Insulin Clinical Trials Clinical Trials Trials 40

BioSpace

MAY 19, 2021

Eli Lilly's SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.

Insulin 53

Insulin Trials 53

BioTech 365

OCTOBER 14, 2021

Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial … Continue reading →

Insulin 40

Insulin Trials 40

BioTech 365

OCTOBER 14, 2021

Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial … Continue reading →

Insulin 40

Insulin Trials 40

BioSpace

OCTOBER 3, 2023

New Phase I/II trial results show that one more type 1 diabetes patient achieved insulin independence after treatment with Vertex Pharmaceuticals’ investigational stem cell therapy VX-880.

Insulin 107

Insulin Trials 107

Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. LAI-287 + semaglutide) overview A fixed dose combination of GLP-1 analogue semaglutide and LAI-287, long-acting basal insulin is under development for the treatment of type 2 diabetes.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

The Pharma Data

JUNE 29, 2021

New Soliqua ® * data shows improved blood sugar control without weight gain versus premixed insulin. Study also shows more people on Soliqua had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin.

Insulin 52

Insulin Medicine Compliance Marketing 52

Pharma Times

DECEMBER 21, 2023

The new guidance followed a review of a clinical trial and real-world evidence by the University of Warwick and Warwick Medical School, funded by the National Institute for Health and Care Research. The new hybrid closed loop systems have proven to be more effective in maintaining healthy blood glucose levels than standard care.

Insulin 105

Insulin Clinical Trials Clinical Trials Production 105

BioTech 365

MAY 13, 2021

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN) Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for … Continue reading →

Insulin 52

Insulin Clinical Trials Clinical Trials Medicine 52

Pharmaceutical Technology

APRIL 28, 2023

FDA approval follows the successful outcomes of the Sustain Forte trial (NCT03989232), the results of which displayed a superior reduction in HbA1c levels with once-weekly semaglutide 2.0mg, in comparison to once-weekly semaglutide 1.0mg, among individuals suffering from type 2 diabetes.

Sales 130

Sales Insulin Marketing FDA Approval 130

Rethinking Clinical Trials

AUGUST 22, 2022

The COVID-OUT Trial is a remotely delivered, Phase 3, de-centralized clinical trial at 6 participating institutions to see if Ivermectin, Metformin or Fluvoxamine would prevent severe COVID-19. Initially, the randomization of the trial was 1:1 Metformin or Placebo. The primary outcome of the trial was negative.

Trials 130

Trials Clinical Trials Clinical Trials Insulin 130

STAT News

SEPTEMBER 29, 2022

Keeping blood glucose in a healthy range requires a constant stream of calculations: counting the carbs in each meal, and then finding the right dose of insulin to balance them out. In the last several years , automated insulin delivery has helped many patients with type 1 diabetes avoid harmful dips and surges in their blood sugar.

Insulin 126

Insulin Clinical Trials Clinical Trials Trials 126

Velocity Clinical Research

JANUARY 16, 2024

Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a similar risk of hypoglycemia.

Insulin 52

Insulin Clinical Trials Clinical Trials Clinical Research 52

Velocity Clinical Research

JUNE 27, 2023

Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. “In In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” said Dr. Rosenstock. “A

Insulin 52

Insulin Trials Hormones Clinical Trials 52

Drug Discovery World

DECEMBER 8, 2022

A Phase III trial has demonstrated that Jardiance (empagliflozin) is the first SGLT2 inhibitor to show a reduction in blood sugar levels in children and adolescents with type 2 diabetes. . The post Positive Phase III trial data for SGLT2 inhibitor in type 2 diabetes appeared first on Drug Discovery World (DDW).

Trials 52

Trials Insulin Clinical Trials Clinical Trials 52

NY Times

NOVEMBER 27, 2021

A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

Insulin 145

Insulin Clinical Trials Clinical Trials Trials 145

Scienmag

DECEMBER 3, 2020

Researchers from the University of Copenhagen and biotech firm Gubra have developed a new insulin molecule that will make blood sugar regulation both easier and safer for those with type 1 diabetes Everyday life for the more than 46 million people around the world who suffer from type 1 diabetes could become much easier and […].

Insulin 40

Insulin Regulation Development Research 40

Rethinking Clinical Trials

AUGUST 18, 2022

The Trial Innovation Network Recruitment Innovation Center aims to positively impact human health by improving participant enrollment and retention in multi-center clinical trials. It leads to physiological changes, it leads to insulin resistance, changes in your immunology. There is plenty of data that shows that.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Insulin 130

XTalks

NOVEMBER 22, 2022

In clinical trials, the treatment delayed stage 3 disease onset for about two years compared with the placebo. Type 1 diabetes, also known as insulin-dependent or juvenile diabetes, is an autoimmune disease that occurs when the body is unable to make enough insulin due to destruction of the beta insulin-producing cells in the pancreas.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

The Pharma Data

DECEMBER 15, 2020

16, 2020 (GLOBE NEWSWIRE) — Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.

Insulin 40

Insulin Clinical Trials Clinical Trials Production 40

pharmaphorum

MAY 21, 2021

Eli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate tirzepatide, setting up regulatory filings for a drug that the drugmaker thinks could be the lynchpin of its franchise in the coming years. . Treatment with Lilly’s drug also resulted in a 11.7

Trials 52

Trials Insulin Sales Drug Delivery 52

Medical Xpress

FEBRUARY 23, 2023

Type 2 diabetes is a chronic disease in which the body does not produce enough of the hormone insulin, which regulates blood sugar, while cells in the muscle, fat and digestive system simultaneously become less sensitive to it, absorbing less sugar from the blood stream.

Insulin 75

Insulin Hormones Regulation Trials 75

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. In the trial, the vaccine was injected directly into the lymph nodes of type 1 diabetic individuals. The DIAGNODE-2 Trial.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

Pharmaceutical Technology

APRIL 20, 2023

The regulatory clearance allows the company to commence its planned Phase IIa placebo-controlled, randomised, crossover, double-blind, multi-centre, multiple-dose trial of ZT-01 to assess its effect on the frequency of nocturnal hypoglycaemia events in Type 1 diabetes mellitus.

Insulin 130

Insulin Trials Drugs 130

Pharmaceutical Technology

JUNE 10, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is a fully human negative allosteric selective insulin receptor modulator (SIRMs) antibody derived from the XMet platform. It was also under development for the treatment of insulinomas.

Insulin 100

Insulin Antibody Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JUNE 10, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is a fully human negative allosteric selective insulin receptor modulator (SIRMs) antibody derived from the XMet platform. It was also under development for the treatment of insulinomas.

Insulin 100

Insulin Antibody Clinical Trials Clinical Trials 100

pharmaphorum

MAY 16, 2022

These examined Mounjaro in 5mg, 10mg and 15 mg doses in five clinical trials, used either as a stand-alone therapy or as an add-on to other diabetes medicines. It was also compared to a placebo, a GLP-1 receptor agonist (semaglutide) and two long-acting insulin analogues. more than insulin degludec and 1.0%

FDA Approval 114

FDA Approval Insulin Drugs Hormones 114